HK Stock Market Move | SIMCERE PHARMA (02096) rises over 2% as it further enters into a collaboration with Lynk Pharmaceuticals on the selective JAK1 inhibitor zepuzetinib

SIMCERE PHARMA (02096) rose over 2%, up 1.96% as of press time to HK$10.39, with a turnover of HK$25.2172 million. On the news front, SIMCERE PHARMA announced that on November 2, 2026, the Group further entered into a collaboration with Lynk Pharmaceuticals (Zhejiang) Co., Ltd. (Lynk Pharmaceuticals) on zepuzetinib, a selective JAK1 inhibitor. The Group will obtain exclusive commercialization rights in mainland China, Hong Kong, Macau, and Taiwan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and other dermatological indications. The Group and Lynk Pharmaceuticals entered into a collaboration in March 2022, obtaining exclusive commercialization rights to zepuzetinib in mainland China, Hong Kong, Macau, and Taiwan for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). This collaboration will further expand the commercialization potential of zepuzetinib and improve the Group's product layout in the autoimmune disease field. In addition, the Phase III clinical study of zepuzetinib for the treatment of rheumatoid arthritis has been completed, and the Phase III clinical development program for ankylosing spondylitis is also underway.